Endocrine Abstracts

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...